Author + information
- Received February 3, 2016
- Revision received March 30, 2016
- Accepted April 21, 2016
- Published online July 25, 2016.
- Konstantinos C. Koskinas, MD, MSca,
- Lorenz Räber, MD, PhDa,∗ (, )
- Thomas Zanchin, MDa,
- Thomas Pilgrim, MDa,
- Stefan Stortecky, MDa,
- Lukas Hunziker, MDa,
- Stefan Blöchlinger, MDa,
- Michael Billinger, MDa,
- Fabienne Gartwyl, BAa,
- Christina Moro, MAa,
- Aris Moschovitis, MDa,
- Peter Jüni, MDb,
- Dik Heg, PhDc and
- Stephan Windecker, MDa
- aDepartment of Cardiology, Bern University Hospital, Bern, Switzerland
- bDepartment of Medicine, University of Toronto, Toronto, Canada
- cInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
- ↵∗Reprint requests and correspondence:
Dr. Lorenz Räber, Bern University Hospital, Department of Cardiology, Freiburgstrasse, Bern 3010, Switzerland.
Objectives The aim of this study was to compare clinical outcomes in relation to the duration of triple antithrombotic therapy (TAT) among patients with indications for oral anticoagulation undergoing percutaneous coronary intervention (PCI).
Background TAT is recommended for patients undergoing PCI with a firm indication for oral anticoagulation. Duration of TAT may influence outcomes, but the optimal period of TAT remains uncertain.
Methods Between 2009 and 2013, 8,772 consecutive patients undergoing PCI for stable coronary artery disease or acute coronary syndrome were prospectively included in the Bern PCI Registry (NCT02241291). Of 568 patients with indications for oral anticoagulation, 245 (43%) were discharged on a regimen of 1-month TAT and 323 (57%) on a regimen >1-month TAT (mean 5.1 ± 3.3 months, median 3 months). The primary endpoint was a composite of cardiac death, myocardial infarction, stroke, definite stent thrombosis, or TIMI (Thrombolysis in Myocardial Infarction) major bleeding within 1 year.
Results Patients on 1-month compared with >1-month TAT were more commonly women, with stable coronary artery disease, had higher HAS-BLED scores, and less frequently received drug-eluting stents. In multivariate analyses, the primary endpoint did not differ between groups (adjusted hazard ratio: 1.07; 95% confidence interval: 0.56 to 2.06; p = 0.84). Results were consistent in stratified analyses in relation to clinical presentation with acute coronary syndrome (38%) and PCI with drug-eluting stents (79%) (p for interaction = 0.18 and 0.95, respectively). There were no differences in the secondary bleeding endpoint, Bleeding Academic Research Consortium ≥3 bleeding (adjusted hazard ratio: 0.62; 95% confidence interval: 0.21 to 1.80; p = 0.37) and the secondary composite ischemic endpoint (cardiac death, myocardial infarction, stroke, or definite stent thrombosis) (adjusted hazard ratio: 1.12; 95% confidence interval: 0.55 to 2.29; p = 0.76).
Conclusions One-month TAT, used preferentially in patients with higher estimated bleeding risk in this observational study, was associated with similar net clinical outcomes compared with longer TAT durations throughout 1 year following PCI.
Dr. Jüni is an unpaid steering committee or statistical executive committee member of trials funded by Abbott Vascular, Biosensors, Medtronic, and St. Jude Medical. Prof. Windecker has received research contracts to the institution from Abbott Vascular, AstraZeneca, Boston Scientific, Biosensors, Biotronik, Cordis, Eli Lilly, Medtronic, and St. Jude Medical. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Koskinas and Räber contributed equally to this work.
- Received February 3, 2016.
- Revision received March 30, 2016.
- Accepted April 21, 2016.
- American College of Cardiology Foundation